Quebec is proposing to prohibit owner pharmacists from procuring generic medications from the same manufacturer in excess of 50% of the monetary value of all the generic medications purchased by that pharmacist during a given calendar year.

Bill 148, An Act to regulate generic medication procurement by owner pharmacists and to amend various legislative provisions, was tabled in the National Assembly on October 5. It will introduce the prohibition through the new Regulation to govern generic medication procurement by owner pharmacists and make other related amendments, mostly to An Act respecting Prescription Drug Insurance.

Pharmacists will have to report annually on their purchases of each brand of generic medication. Fines of up to $100,000 are provided for failure to comply with the new regulation.

The bill has been referred to the Committee on Health and Social Services for special consultations, with public hearings scheduled for November 7 and 8. Comments on the bill can be made online, but only until November 8.1

Since 2015, Bills 28, 81 and, most recently, 92 have made significant changes to the way the prescription drug insurance regime is governed in Quebec. Most of those new measures aimed to reduce the cost of providing public drug insurance. A number were intended to enhance competition within the drug market in the hope of reducing drug prices and, hence, insurance costs. Bill 148 appears to fit within the latter policy, designed to encourage a multiplicity of suppliers, presumably with a view to increasing competition and, therefore, reducing prices. Whether this will have the desired effect remains to be seen. It is also plausible it might have the opposite effect, forcing pharmacists to diversify their sources of supply even if doing so increases costs.

Footnote

1 https://www.assnat.qc.ca/en/travaux-parlementaires/commentaire.html?type=ProjetLoi&id=16281&url=travaux-parlementaires/projets-loi/projet-loi-148-41-1


About Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.

Law around the world
nortonrosefulbright.com

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.